Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

Hikma has completed its acquisition of Xellia Pharmaceuticals’ U.S. finished dosage form business and related assets following clearance under applicable U.S. antitrust laws. The acquisition ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million people worldwide Riyadh – Hikma Pharmaceuticals KSA, announced the ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... In 2021, Xyrem generated over $1.8 billion in revenue for Jazz. Jazz has denied the allegations, stating that the judge’s order ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia.